Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Kidney Cancer
Melanoma (Skin)

Interventions: Biological: filgrastim
Biological: therapeutic allogeneic lymphocytes
Drug: cyclophosphamide
Drug: fludarabine phosphate
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2014-03-07

Lead Sponsor: University of Chicago

Target Recruit Count: 19

Registration Number: NCT00004135

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma

Phase 3

Completed

Conditions: Lymphoma

Interventions: Biological: rituximab
Drug: CHOP regimen
Drug: cyclophosphamide
Drug: carmustine
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate
Drug: etoposide
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2021-02-02

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 397

Registration Number: NCT00004031

Locations: 🇨🇦
Moncton Hospital, Moncton, New Brunswick, Canada
🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
🇨🇦
Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada

and more 12 locations

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Phase 3

Completed

Conditions: Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2014-02-14

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 483

Registration Number: NCT00002995

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 229 locations

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Biological: filgrastim
Biological: sargramostim
Drug: cyclophosphamide
Drug: dexamethasone
Drug: melphalan
Drug: prednisone
Drug: thalidomide
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2016-12-08

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 147

Registration Number: NCT00040937

Locations: 🇺🇸
Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States
🇺🇸
Community Medical Center, Missoula, Montana, United States
🇺🇸
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center, Missoula, Montana, United States

and more 138 locations

Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Biological: filgrastim
Drug: docetaxel
Drug: cyclophosphamide
Genetic: microarray analysis
Drug: epirubicin hydrochloride
Drug: fluorouracil
Other: laboratory biomarker analysis
Other: immunohistochemistry staining method
Procedure: biopsy
Procedure: neoadjuvant therapy
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-10-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 1856

Registration Number: NCT00017095

Locations: 🇬🇧
Edinburgh Cancer Centre at Western General Hospital, Edinburgh, Scotland, United Kingdom
🇵🇹
Instituto Portugues de Oncologia de Francisco Gentil - Centro Regional de Oncologia de Lisboa, S.A., Lisbon, Portugal
🇨🇭
Inselspital Bern, Bern, Switzerland

and more 36 locations

Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Biological: filgrastim
Biological: recombinant interferon alfa
Drug: busulfan
Drug: cyclophosphamide
Drug: melphalan
Drug: pamidronate disodium
Drug: thalidomide
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2019-07-02

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 77

Registration Number: NCT00004088

Locations: 🇺🇸
Banner Good Samaritan Medical Center, Phoenix, Arizona, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: AC regimen
Drug: doxorubicin hydrochloride
Drug: paclitaxel
Drug: cyclophosphamide

First Posted Date: 2003-01-27

Last Posted Date: 2017-05-18

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 3871

Registration Number: NCT00041119

Locations: 🇺🇸
UVMC Cancer Care Center at Upper Valley Medical Center, Troy, Ohio, United States
🇺🇸
Bismarck Cancer Center, Bismarck, North Dakota, United States
🇺🇸
Dubs Cancer Center at Rogue Valley Medical Center, Medford, Oregon, United States

and more 519 locations

Combination Chemotherapy in Treating Children With Neuroblastoma

Phase 3

Completed

Conditions: Neuroblastoma

Interventions: Biological: filgrastim
Biological: sargramostim
Drug: carboplatin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Procedure: conventional surgery
Procedure: neoadjuvant therapy

First Posted Date: 2003-01-27

Last Posted Date: 2014-08-01

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 573

Registration Number: NCT00003093

Locations: 🇺🇸
Columbus Children's Hospital, Columbus, Ohio, United States
🇺🇸
Cancer Research Center of Hawaii, Honolulu, Hawaii, United States
🇺🇸
MBCCOP - Hawaii, Honolulu, Hawaii, United States

and more 231 locations